Molecular characterization of canine SHP2 mutants and anti‐tumour effect of SHP2 inhibitor, SHP099 , in a xenograft mouse model of canine histiocytic sarcoma-Reference-Cited by-同舟云学术

Molecular characterization of canine SHP2 mutants and anti‐tumour effect of SHP2 inhibitor, SHP099 , in a xenograft mouse model of canine histiocytic sarcoma

Published:2021-07-26 Issue: Volume: Page:
ISSN:1476-5810
Container-title:Veterinary and Comparative Oncology
language:en
Short-container-title:Vet Comp Oncol

Author:

Tani Hiroyuki¹,Miyamoto Ryo¹,Nagashima Tomokazu²³,Michishita Masaki³⁴,Tamura Kyoichi¹,Bonkobara Makoto¹⁴^ORCID

Affiliation:

1. Department of Veterinary Clinical Pathology Nippon Veterinary and Life Science University Tokyo Japan

2. Veterinary Medical Teaching Hospital Nippon Veterinary and Life Science University Tokyo Japan

3. Department of Veterinary Pathology Nippon Veterinary and Life Science University Tokyo Japan

4. Research Center for Animal Life Science Nippon Veterinary and Life Science University Tokyo Japan

Funder

Japan Society for the Promotion of Science

Publisher

Wiley

Subject

General Veterinary

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/vco.12751

Reference21 articles.

1. Clinical prognostic factors in canine histiocytic sarcoma;Dervisis NG;Vet Comp Oncol.,2017

2. CCNU for the treatment of dogs with histiocytic sarcoma;Skorupski KA;J Vet Intern Med.,2007

3. Phase II, open‐label trial of single‐agent CCNU in dogs with previously untreated histiocytic sarcoma;Rassnick KM;J Vet Intern Med.,2010

4. The SHP‐2 tyrosine phosphatase: signaling mechanisms and biological functions;Qu CK;Cell Res.,2000

5. The tyrosine phosphatase SHP‐2 is required for mediating phosphatidylinositol 3‐kinase/Akt activation by growth factors;Wu CJ;Oncogene.,2001

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. One Health: Therapies Targeting Genetic Variants in Human and Canine Histiocytic and Dendritic Cell Sarcomas;Veterinary and Comparative Oncology;2024-06-12